Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
225.50
-1.58 (-0.70%)
At close: Mar 24, 2026, 4:00 PM EDT
225.28
-0.22 (-0.10%)
After-hours: Mar 24, 2026, 6:02 PM EDT
Insulet Employees
Insulet had 5,400 employees as of December 31, 2025. The number of employees increased by 1,500 or 38.46% compared to the previous year.
Employees
5,400
Change (1Y)
1,500
Growth (1Y)
38.46%
Revenue / Employee
$501,500
Profits / Employee
$45,759
Market Cap
15.87B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,400 | 1,500 | 38.46% |
| Dec 31, 2024 | 3,900 | 900 | 30.00% |
| Dec 31, 2023 | 3,000 | 400 | 15.38% |
| Dec 31, 2022 | 2,600 | 300 | 13.04% |
| Dec 31, 2021 | 2,300 | 400 | 21.05% |
| Dec 31, 2020 | 1,900 | 550 | 40.74% |
| Dec 31, 2019 | 1,350 | 181 | 15.48% |
| Dec 31, 2018 | 1,169 | 312 | 36.41% |
| Dec 31, 2017 | 857 | 217 | 33.91% |
| Dec 31, 2016 | 640 | -7 | -1.08% |
| Dec 31, 2015 | 647 | 128 | 24.66% |
| Dec 31, 2014 | 519 | 41 | 8.58% |
| Dec 31, 2013 | 478 | -60 | -11.15% |
| Dec 31, 2012 | 538 | -38 | -6.60% |
| Dec 31, 2011 | 576 | 266 | 85.81% |
| Dec 31, 2010 | 310 | 34 | 12.32% |
| Dec 31, 2009 | 276 | -18 | -6.12% |
| Dec 31, 2008 | 294 | 47 | 19.03% |
| Dec 31, 2007 | 247 | -47 | -15.99% |
| Dec 31, 2006 | 294 | 47 | 19.03% |
| Dec 31, 2005 | 247 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Koninklijke Philips | 65,340 |
| GE HealthCare Technologies | 54,000 |
| Smith & Nephew | 18,060 |
| STERIS | 17,787 |
| Zimmer Biomet Holdings | 17,000 |
| DexCom | 11,100 |
| Bio-Rad Laboratories | 7,450 |
| Bio-Rad Laboratories | 7,450 |
PODD News
- 12 days ago - Insulet recalls some insulin devices in US over leakage risk - Reuters
- 12 days ago - Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S. - Business Wire
- 13 days ago - Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes - Business Wire
- 14 days ago - Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Business Wire
- 26 days ago - Insulet: The Growth Doesn't Stop Here - Seeking Alpha
- 4 weeks ago - Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations - Seeking Alpha
- 4 weeks ago - Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars - Benzinga